DOCS: What the Options Saw First

The Signal

Before Doximity (DOCS) reported a single number on the evening of August 6, the options market was already speaking. Pre-earnings options volume ran at 6.1 times normal levels, with calls leading puts at a ratio of roughly 9 to 7. The 30-day implied volatility on DOCS was sitting at 103, against a 52-week range of 31 to 127, placing it near the elevated end of its annual volatility band. The at-the-money straddle priced in a post-earnings move of approximately 14.1%, or about $2.90 on a stock trading near $20.66 heading into the report.

That was the market’s collective bet. Sophisticated? Directionally leaning bullish, given the call skew. Accurate in magnitude? Not even close. DOCS gapped more than 130% in overnight trading before settling. It closed August 7 up 33% on the session, with intraday prints reaching 55% above the prior close before the reversal. Volume on the day hit 65.32 million shares against an average daily volume of 11.63 million. The options market, despite elevated implied volatility, dramatically underpriced what was about to happen.

That gap between what volatility priced and what actually occurred is the first signal worth examining. It is not a failure of the options market. It is a case study in what happens when a catalyst contains information that the market, even in an elevated-IV environment, could not fully anticipate. Understanding that distinction is what separates a post-event recap from actual options intelligence.

Why It Matters

Options traders were not positioned for a 33% move. The implied move of 14.1% told you that. The historical median earnings move for DOCS over the prior eight quarters was 20.5%, which already argued the options market was pricing the event too lightly relative to history. But even that historical anchor offered no warning for a same-session close north of 30%.

Why does that matter now, when the event has already passed? Because what happens in the days and weeks following a volatility event of this magnitude is where the next set of options opportunities lives. Post-earnings IV crush is the standard outcome. After a catalytic spike of this size, implied volatility typically collapses back toward its historical baseline, and it collapses fast. Traders who bought options pre-event and held them through the move often watch significant vega evaporate even when they are directionally correct on a smaller scale. That dynamic is now fully in play for DOCS.

Additionally, a 33% single-session gain on a stock that was down roughly 50% year to date before earnings creates a specific technical and options-market condition: elevated realized volatility against a falling implied volatility. That spread, the gap between what has happened and what the market is now pricing, is precisely where defined-risk strategies tend to offer the most interesting risk-adjusted structures. This is not about chasing the move. It is about reading what the volatility market is telling us about the next chapter.

The Company Behind the Signal

Doximity is a digital platform that counts more than 85% of U.S. physicians among its network members. Its primary revenue model has historically been pharmaceutical digital marketing, connecting drug makers to physicians at the point of clinical influence. That business is high-margin, capital-light, and deeply embedded in the way healthcare professionals consume professional information.

The reason the stock spent much of 2026 under pressure was equally specific: softer pharma advertising budgets, a CFO transition, and serious skepticism about whether the company’s AI investment cycle would produce commercial returns before margin compression became a problem. Operating cash flow fell more than 30% year over year in fiscal Q1, dropping to $42.0 million. Free cash flow tracked similarly at $39.6 million. The market penalized that compression, Bank of America went as far as downgrading to Underperform with a $20 price target, and short interest climbed to roughly 10% of shares outstanding heading into the report.

The catalyst that reversed all of that in a single session was CEO Jeff Tangney’s disclosure on the August 6 earnings call: Doximity’s AI Search product is currently earning more than 10 times per search in revenue than it costs to run. That unit economics figure landed in a market that had priced the AI bet as unproven and potentially dilutive. The repricing was immediate and violent.

The underlying business delivered fiscal Q1 revenue of $156.6 million, a 7% year-over-year increase, with adjusted EBITDA of $74.8 million, both above consensus. EPS came in at $0.29, a penny above estimates. Net revenue retention for the top 20 clients reached 112%. The company now has 127 enterprise customers generating more than $500,000 in annual recurring revenue. Full-year fiscal 2027 revenue guidance was raised to $671 million to $681 million. Workflow-active prescriber growth exceeded 30% year over year. AI Search queries jumped more than 25% sequentially.

No AI Search revenue was recognized in fiscal Q1. More than 100 leading health systems have purchased the AI suite. The revenue conversion is expected to begin building in the second half of fiscal 2027. That gap between adoption and monetization is, for options traders, a forward-looking catalyst timeline, not just a business narrative.

Market Expectations: What Was Priced, What Was Not

Going into the August 6 report, the options market was pricing three things simultaneously. First, elevated uncertainty: at 103 implied volatility against a 52-week range of 31 to 127, the market acknowledged meaningful event risk without pricing a catastrophic or euphoric outcome. Second, a moderate directional lean toward calls, with the pre-event put/call ratio running roughly 0.78 (9 calls to 7 puts on elevated volume). Third, a magnitude expectation of 14.1%.

All three reads were reasonable given the available information. What the options market could not price was the specific content of Tangney’s unit economics disclosure, the NOHARM clinical benchmark result, or the degree to which short sellers would be mechanically forced to cover. The median historical earnings move of 20.5% over the prior eight quarters suggested the market was already slightly underpricing event risk on a historical basis. The actual move at close of 33%, with intraday peaks near 55%, was a multi-standard-deviation outcome.

For traders who held long options into the event, the outcome was extraordinary for directionally correct positions, but the IV crush that followed the event would have eroded positions on smaller moves. This is the standard post-earnings dilemma, and DOCS provides an unusually clear example of both the upside and the structural challenge of long volatility positioning through catalysts.

Post-event, the analyst community moved swiftly. Needham raised its target to $41 from $27. Raymond James moved to $38 from $23. Evercore ISI went to $40 from $22. Morgan Stanley reiterated its Buy rating, noting that AI search momentum was building faster than expected. Piper Sandler’s Jessica Tassan wrote that management appeared to be taking a conservative approach to AI search revenue in the FY27 outlook, suggesting the guidance raise may not yet reflect a significant contribution from the expanding AI commercial pipeline. That analyst read is directly relevant to how forward options are now being priced.

Options Market Analysis: Post-Event Volatility Landscape

The pre-earnings IV of 103 against a 52-week low of 31 placed DOCS in an elevated but not extreme percentile of its own volatility range. Post-event, implied volatility across near-term expiries will have collapsed as the primary catalyst resolved. This is the standard IV crush dynamic: the event risk premium that inflates options pricing ahead of earnings deflates sharply once the binary outcome is known, regardless of direction.

What makes the post-DOCS environment interesting is the interplay between realized and implied volatility. DOCS just printed one of the largest single-session earnings moves in its history. The 52-week high of $76.51 and low of $17.15 define an unusually wide realized volatility band for a mid-cap healthcare software company. That realized volatility history will support elevated implied readings in forward months even as the immediate post-event IV crush sets in.

The August 21 expiry is the nearest cycle with significant open interest following the event. The next meaningful catalyst on the calendar is the fiscal Q2 report, expected in early November, which introduces a multi-month window where the primary driver of DOCS options pricing shifts from event risk to directional positioning around the AI Search revenue ramp thesis.

The call flow signal heading into earnings was directionally correct. The put/call ratio of roughly 0.78 on 6.1 times normal volume suggested institutional participants were leaning toward upside exposure rather than hedging downside. That positioning was validated. The more relevant question now is whether that bullish positioning has been fully unwound, or whether fresh call flow has entered the market in the post-event session, reflecting traders who missed the move and are now sizing into longer-dated upside structures.

On the short squeeze dimension: short interest stood at approximately 10.26% of shares outstanding heading into the report. Trading volume on August 7 at 65.32 million shares represented more than five times average daily volume of 11.63 million. The mechanical covering pressure from short sellers forced to unwind positions into a rising market contributed to the velocity of the intraday move, even if the fundamental catalyst supplied the initial spark. Post-event, that short covering is largely complete, removing a structural tailwind that will not repeat on the next move.

Strategic Considerations: Three Frameworks for Three Outlooks

The options strategies appropriate for DOCS now differ significantly from what would have applied before the earnings event. The post-event environment is defined by: a large gap higher in the underlying, collapsing near-term implied volatility, a multi-month wait before the next major catalyst, and a fundamental story where the key variable (AI Search revenue conversion) remains forward-looking. Each of the following frameworks reflects a different view of how that story resolves.

Bull Case: Defined Upside Exposure Without Overpaying for Vega

For traders who believe the AI Search revenue ramp will materialize in the back half of fiscal 2027 and that Piper Sandler’s read is correct that guidance is conservative, the challenge is entering upside exposure after a 33% move without paying the inflated premiums that characterized pre-event pricing.

A defined-risk structure worth considering in this environment is a call debit spread using the November or January expiry, targeting strikes that sit above the current price but below the levels where analyst targets cluster. For example, if traders expecting continued appreciation toward the $36 to $41 range identified by Canaccord and Needham want exposure with capped downside, a debit call spread with the long leg near current trading levels and the short leg at or near those analyst targets captures the expected move at a fraction of the cost of an outright call, while limiting exposure to further IV compression as time passes between now and the Q2 report.

The risk to this structure is time decay working against the position across the multi-month window before the next catalyst. If AI Search revenue recognition slips from the expected back-half timeline, the stock may drift lower without a near-term event to act as a re-rating trigger. The spread structure limits this risk relative to a straight long call but does not eliminate it.

Bear Case: Fading the Post-Event Euphoria with Defined Risk

The bear case is not a bet against Doximity’s AI strategy. It is a structural observation: the stock absorbed years of pessimism and then revalued by one-third in a single session, with no AI Search revenue yet recognized, a contested clinical benchmark, and free cash flow down more than 30% year over year. That is a significant amount of faith priced into a future that has not yet arrived.

For traders who believe the post-event move has overshot fair value given current fundamentals, a put debit spread positioned below recent support, using the November expiry, offers a way to express that view with defined maximum loss. The key risk here is that IV crush after the event makes puts materially cheaper than they were before the report, which actually favors put buyers who missed the pre-event window. If IV has dropped sharply, long puts are cheaper. The tradeoff is that any near-term positive development around AI Search commercialization could punish downside positions quickly.

This is not a thesis for traders who believe Doximity’s AI bet fails outright. It is for those who believe the market has simply gotten ahead of a commercial ramp that will take longer than the current price implies, and who want a defined-risk way to express that timing mismatch.

Neutral Case: Selling Elevated Volatility into the Quiet Window

If the view is that DOCS settles into a range between current levels and the lower end of analyst targets while the market waits for Q2 revenue data, the most appropriate structure in a post-event, declining-IV environment is a premium-selling approach. An iron condor or a short strangle using the next expiry cycle captures the remaining implied volatility premium while the stock digests the move.

The significant risk with a neutral structure on DOCS specifically is that this is not a range-bound stock with a stable volatility history. The 52-week realized price range of $17.15 to $76.51 argues that directional moves can be large and fast. A neutral, premium-selling structure should be positioned with wide enough wings to survive another sharp move in either direction. Undefined-risk short options strategies would be inappropriate given this stock’s demonstrated capacity for multi-standard-deviation outcomes. A defined structure such as an iron condor with strikes placed at meaningful technical distances is the only sensible framework for a neutral view.

Risk Analysis

Three risks deserve explicit framing for any options positioning in DOCS from this point forward.

Benchmark credibility. The NOHARM study placing Doximity Ask as the top-performing U.S.-based clinical AI model was challenged by OpenEvidence CEO Daniel Nadler, who questioned the methodology and expressed doubt about whether the study would survive peer review. A replication failure or a competing study with different results could reintroduce the AI skepticism that the market just shed. That would be a fast-moving negative catalyst for a stock that has priced in significant clinical AI credibility.

Revenue timing risk. Full-year guidance of $671 million to $681 million implies mid-single-digit growth at the midpoint, with management explicitly noting that the AI Search revenue ramp is weighted toward the back half of the fiscal year. The guidance raise of $6 million at the midpoint did not, per Piper Sandler’s read, reflect meaningful AI Search commercial revenue. If Q2 results show continued engagement without revenue conversion, the stock’s premium valuation relative to current earnings will face pressure.

Cash flow compression and multiple sensitivity. Operating cash flow fell more than 30% year over year to $42.0 million in fiscal Q1, with free cash flow at $39.6 million. The company repurchased $91.6 million of stock in the same quarter, a buyback pace that exceeds free cash flow generation. At post-event valuations, the stock is no longer priced for a pessimistic outcome. Any further margin compression or delay in AI Search monetization will be felt more acutely at higher price levels than at the pre-event trough.

Forward Outlook

The post-event options landscape for DOCS is defined by a specific set of forces that will interact over the next three to four months. Implied volatility will compress as the catalyst window closes and the next material event (fiscal Q2 earnings, expected in early November) remains months away. Realized volatility will remain elevated on a trailing basis given what just happened, creating a basis where forward implied readings may stay higher than they would in a quieter stock, even without a near-term catalyst.

The fundamental story has a clear inflection point on the calendar: Q2 revenue results. That report will either begin confirming that AI Search health system contracts are converting to recognized revenue, or it will reveal that the conversion is slower than the post-event price implies. Nothing that happens in the interim, no analyst note, no benchmark update, no competitor announcement, will resolve that question the way a revenue line on a balance sheet will.

The state-level regulatory environment compounds the thesis in Doximity’s favor on a longer horizon. A wave of 2026 state laws governing AI use in healthcare, many requiring human oversight before AI-assisted clinical decisions reach a patient, structurally advantages platforms where physicians are already embedded in the review loop. That regulatory direction is not priced as a quarterly event. It is a multi-year positioning advantage for a company whose PeerCheck architecture is already built for that compliance environment.

The pharma channel dimension is the longer-term wildcard. Doximity’s AI Search is opening engagement with senior pharmaceutical executives at a level the company did not initially model. A platform with proven reach to 85% of U.S. physicians, combined with AI-powered targeting at the point of prescribing intent, is a fundamentally different advertising channel from anything currently running at scale in healthcare digital marketing. That opportunity is real. It is also unmeasured, early-stage, and not yet in any guidance figure. The options market will begin pricing that potential only when revenue data confirms the channel is converting.

Action Checklist

• Monitor post-event IV compression. Track 30-day implied volatility on DOCS over the next two weeks. The degree of crush from the pre-event level of 103 will determine whether long or short vega structures offer better risk-adjusted setups going forward.
• Watch put/call ratio on the August 21 expiry. If put buying accelerates as the stock stabilizes, it may indicate institutional hedging of new long positions taken at post-event levels, a signal that smart money is managing downside rather than exiting.
• Track open interest shifts in the $30 to $40 strike range. Concentration of open interest in that zone across the October or November expiry would indicate the market is pricing a continued move toward analyst target clusters over the next quarter.
• Flag any NOHARM benchmark developments. If peer review results, a competing study, or a methodological rebuttal from Doximity surfaces, implied volatility will respond. This is the most binary non-earnings catalyst on the horizon for DOCS options.
• Mark the fiscal Q2 earnings date. Expected in early November, this report is the only catalyst that can confirm or deny the AI Search revenue conversion thesis. Options structures with November expiry should account for renewed event-risk premium pricing beginning approximately three to four weeks before the announcement.
• Assess free cash flow versus buyback pace in Q2. The company repurchased $91.6 million of stock against $39.6 million in free cash flow in Q1. If that pace continues without a commensurate improvement in cash generation, it becomes a structural concern that could weigh on valuation multiples regardless of AI Search progress.
• For defined-risk bull structures: If you believe AI Search revenue begins recognizing in Q2 and guidance proves conservative, a call debit spread targeting the $36 to $40 range on the November expiry captures that thesis with capped loss and defined maximum gain.
• For defined-risk neutral structures: If you believe the stock settles into a multi-month consolidation range while the market waits for revenue data, a wide iron condor using the October expiry, positioned outside the implied one-standard-deviation move, captures declining volatility premium while the fundamental story develops.

The options market told us something before DOCS reported. The call flow, the elevated IV, the 6.1 times normal volume, all pointed to an event with directional lean and meaningful magnitude. The market underestimated the size of the move because it could not price a specific piece of information it did not yet have. That is how catalysts work. The analysis from here is not about what happened on August 7. It is about what the options market will price between now and early November, and whether the signals it sends in that window align with a business that has made one extraordinary disclosure and must now turn it into a revenue line.

The Options Trading Report will be watching.